ADMA Biologics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $121,984 | $114,802 | $117,549 | $119,839 |
Gross Profit | 67,227 | 61,097 | 63,333 | 59,659 |
EBITDA | 43,989 | 37,394 | 39,536 | 42,188 |
EBIT | 41,931 | 35,425 | 37,592 | 40,248 |
Net Income | 34,219 | 26,904 | 111,896 | 35,909 |
Net Change In Cash | 121,984 | 114,802 | 117,549 | 119,839 |
Free Cash Flow | 18,717 | -24,376 | 47,466 | 24,286 |
Cash | 90,285 | 71,625 | 103,147 | 86,707 |
Basic Shares | 248,608 | 244,676 | 245,901 | 244,804 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $426,454 | $258,215 | $154,079 | $80,942 |
Gross Profit | 219,553 | 88,942 | 35,265 | 1,173 |
EBITDA | 147,689 | 5,120 | -39,722 | -53,334 |
EBIT | 139,644 | -3,212 | -46,835 | -58,830 |
Net Income | 197,673 | -28,239 | -85,183 | -84,452 |
Net Change In Cash | 426,454 | 258,215 | 154,079 | 80,942 |
Cost of Revenue | 35,432 | -4,832 | ||
Free Cash Flow | 110,097 | 3,819 | -73,419 | -125,880 |
Cash | 103,147 | 51,352 | 86,521 | 51,089 |
Basic Shares | 243,342 | 223,977 | 197,874 | 139,578 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $0.14 |
2025-03-31 | $0.11 |
2024-12-31 | $0.13 |
